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Abstract
Objective—Neonatal-onset multisystem inflammatory disease (NOMID; also known as chronic 
infantile neurologic, cutaneous, articular [CINCA] syndrome) is characterized by fever, chronic 
meningitis, uveitis, sensorineural hearing loss, urticarial skin rash, and a characteristic deforming 
arthropathy. We investigated whether patients with this disorder have mutations in CIAS1, the 
gene which causes Muckle-Wells syndrome and familial cold autoinflammatory syndrome, two 
dominantly inherited disorders with some similarities to NOMID/CINCA syndrome.
Methods—Genomic DNA from 13 patients with classic manifestations of NOMID/CINCA 
syndrome and their available parents was screened for CIAS1 mutations by automated DNA 
sequencing. Cytokine messenger RNA (mRNA) levels were assessed by real-time polymerase 
chain reaction on peripheral blood leukocyte mRNA, and serum cytokine levels were assayed by 
enzyme-linked immunosorbent assay. Protein expression was assessed by Western blotting of 
lysates from plastic-adherent peripheral blood mononuclear cells.
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Results—In 6 of the 13 patients, we found 6 heterozygous missense substitutions in CIAS1. Five 
of the 6 mutations are novel. None of these sequence changes was observed in a panel of >900 
chromosomes from healthy controls. Two distinct nucleotide changes in a single codon in 
unrelated patients resulted in the same amino acid change. In 4 mutation-positive children whose 
parental DNA was available, no mutation was found in the parental DNA, supporting the 
conclusion that the mutations arose de novo. Consistent with the recently discovered role of CIAS1 
in the regulation of interleukin-1 (IL-1), we found evidence of increased IL-1β, as well as tumor 
necrosis factor, IL-3, IL-5, and IL-6, but not transforming growth factor β, in a mutation-positive 
patient compared with normal controls.
Conclusion—Our data increase the total number of known germline mutations in CIAS1 to 20, 
causing a spectrum of diseases ranging from familial cold autoinflammatory syndrome to Muckle-
Wells syndrome to NOMID/CINCA syndrome. Mutations in CIAS1 were only found in ~50% of 
the cases identified clinically as NOMID/CINCA syndrome, which raises the possibility of genetic 
heterogeneity. IL-1 regulation by CIAS1 suggests that IL-1 receptor blockade may constitute a 
rational approach to the treatment of NOMID/CINCA syndrome.
The systemic autoinflammatory diseases are a group of disorders characterized by episodic 
or fluctuating degrees of inflammation without evidence of hightiter autoantibodies or 
antigen-specific T cells (1–3). Within the last 5 years, the genetic basis of several 
autoinflammatory diseases with Mendelian inheritance, including familial Mediterranean 
fever (FMF) (4,5), familial Hibernian fever (now renamed the tumor necrosis factor 
receptor–associated periodic syndrome [TRAPS]) (1), the hyperimmunoglobulinemia D 
with periodic fever syndrome (HIDS) (6–8), Muckle-Wells syndrome (MWS) (9), familial 
cold autoinflammatory syndrome (FCAS; formerly known as familial cold urticaria) (9), and 
Blau syndrome (10), has been identified.
At the outset of the current studies, the molecular basis of another likely autoinflammatory 
syndrome, known in North America as neonatal (or infantile)–onset multisystem 
inflammatory disease (NOMID) (11–13) and in Europe as chronic infantile neurologic, 
cutaneous, and articular (CINCA) syndrome (14,15), had not been elucidated. Patients with 
NOMID/CINCA syndrome present with a severe but unexplained phenotype, including 
dermatologic, arthropathic, and neurologic symptoms (for review, see refs. 16 and 17). An 
urticaria-like skin rash is often present from birth. A highly characteristic arthropathy, with 
distinctive radiographic findings of premature patellar and epiphyseal long bone ossification 
and resultant osseous overgrowth (18,19), often develops early in life and leads to severe 
contractures and disability. Neurologic manifestations, including chronic aseptic meningitis, 
cerebral ventricular dilation, cerebral atrophy, uveitis, optic disc edema, high-frequency 
hearing loss, and mental retardation, are present in various subsets of patients. Short 
episodes of recurrent fevers are frequently noted. Approximately 20% of patients die before 
reaching young adulthood (16).
Findings suggestive of an ongoing inflammatory process include lymphadenopathy, 
splenomegaly, a prolonged erythrocyte sedimentation rate, leukocytosis, eosinophilia, and 
hyperglobulinemia, but autoantibodies are generally not present. A few families with more 
than one affected member have been described (20,21), and unrelated patients often have a 
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sibling-like resemblance, but genetic studies have been hampered by the fact that most cases 
are sporadic.
With the recent identification of the genes that cause other autoinflammatory syndromes, we 
considered the possibility that abnormalities in one of these newly discovered genes might 
also cause NOMID/CINCA syndrome. CIAS1 (9), the gene underlying FCAS and MWS, 
was a particularly attractive candidate because of clinical similarities between these 
syndromes, including fever and urticarial rash, with dermal polymorphonuclear leukocytes 
seen in FCAS (22), MWS (23), and NOMID/CINCA syndrome, and with lymphadenopathy 
and sensorineuronal hearing loss seen in MWS (23) and NOMID/CINCA syndrome. CIAS1 
is located on chromosome 1 and belongs to a newly recognized family of genes that encodes 
proteins that share a structural motif with pyrin (or marenostrin), the FMF protein. The 
amino terminus of pyrin encodes an ~90–amino acid motif (the PYRIN domain) found in a 
number of regulators of the inflammatory response and apoptosis (3,24–30). The PYRIN 
domain bears 3-dimensional structural similarities to death domains, death-effector domains, 
and caspase-recruitment domains, and is thought to be important in homotypic protein–
protein interactions. The product of CIAS1, cryopyrin (also called PYPAF1 or NALP3), has 
been shown to activate nuclear factor κB (NF-κB) (31), and it may also regulate 
interleukin-1 (IL-1) processing through PYRIN domain–mediated caspase 1 signaling (32).
We hypothesized that mutations in cryopyrin might have a profound proinflammatory effect, 
as is seen in NOMID/CINCA syndrome. To test the hypothesis that CIAS1 mutations cause 
NOMID/CINCA syndrome, we sequenced this gene in 13 patients. While in the process of 
preparing a manuscript describing our findings, Feldmann and colleagues (33) reported 7 
different CIAS1 mutations in 7 unrelated cases of NOMID/CINCA syndrome. One of the 
mutations identified in our screen is the same as 1 of the 7 mutations reported by Feldmann 
et al; the other 5 mutations we identified are novel. We also examine the issue of genetic 




The present study included 12 Caucasian patients and 1 African American patient referred to 
the National Institute of Arthritis and Musculoskeletal and Skin Diseases for molecular 
evaluation of unexplained systemic inflammatory disease. The study was approved by the 
institutional review board at the National Institutes of Health, and written informed consent 
was obtained from the subjects or their parents. All of the patients included in this study had 
been clinically evaluated by physicians experienced in the diagnosis of NOMID/CINCA 
syndrome (BSA, PD, DG, DJL, TLM, RR, or KS). Five patients included in this study have 
been subjects of previous studies (11,19,34).
Mutation detection
Genomic DNA was extracted from whole blood using a commercially available kit 
(Puregene; Gentra Systems, Minneapolis, MN). Mutation detection was performed by 
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bidirectional fluorescence sequencing with dye-primer chemistry (Amersham, Piscataway, 
NJ) on an ABI 377 automated sequencer (Applied Biosystems, Foster City, CA) as 
previously described (1).
Mutation screening in controls
A panel of Caucasian control DNA samples was tested for the presence of the 6 CIAS1 
mutations that were identified in NOMID/CINCA syndrome patients. All of the detected 
mutations were found in the Caucasian children. For the D303N mutation, we developed a 
Taq I restriction endonuclease assay using the following primers: forward 5′-GAC-CTG-
ATC-ATG-AGC-TGC-TGC-3′ and reverse 5′-GCT-CGT-CAA-AGG-CAC-CTT-GCA-
GCT-CAT-3′. The presence of the mutation abolishes a Taq I restriction site. All 6 of the 
mutations were screened by multiple-base extension and mass spectroscopy (MassArray 
Genotyping System; Sequenom, San Diego, CA).
Immunoblotting
Peripheral blood mononuclear cells (PBMCs) were isolated from 40 ml of heparinized blood 
and cultured with or without 1 µg/ml of Escherichia coli O127:B7 lipopolysaccharide 
(Sigma, St. Louis, MO). The cells were then lysed in buffer containing 0.5% Triton X-100, 
300 mM NaCl, 50 mM Tris HCl (pH 7.5), 2 mM EDTA, and complete proteinase inhibitor 
(Roche, Gipf-Oberfrick, Switzerland). The total protein concentrations of the cell lysates 
were measured by bicinchoninic acid reagent (Pierce, Rockford, IL). A total of 12 µg of 
protein was loaded onto 16% Tris glycine gels (Invitrogen, Carlsbad, CA) for sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis and analyzed by Western blotting with 
goat polyclonal anti-human IL-1β (0.5 µg/ml; R&D Systems, Minneapolis, MN).
Quantitative real-time polymerase chain reaction (PCR) of cytokine mRNA expression
Total RNA was isolated from PBMCs using an RNeasy Mini kit (Qiagen, Valencia, CA). 
For real-time PCR experiments, complementary DNA was reverse-transcribed from 1 µg of 
total RNA by using a first-strand complementary DNA synthesis kit (Roche) and analyzed 
with the ABI Prism 7700 Sequence Detection System (Applied Biosystems). Commercially 
available IL-1β, IL-3, IL-5, IL-6, transforming growth factor β1 (TGFβ1), and GAPDH 
probe and primer sets (Applied Biosystems) were used to determine cytokine mRNA 
expression by PBMCs. All samples were normalized to the GAPDH internal positive 
control. The relative cytokine levels are presented as the percentage of control PBMC 
values.
Serum cytokine concentrations
Concentrations of the following serum cytokines were determined using a sandwich 
enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems): tumor necrosis factor 
(TNF), IL-1 receptor antagonist (IL-1Ra), IL-6, and TGFβ1.
Aksentijevich et al. Page 4














Characteristics of the patient cohort
A total of 13 NOMID/CINCA syndrome patients (6 males, 7 females), ranging in age from 5 
to 33 years, were evaluated for mutations in the CIAS1 gene (Figure 1). All 13 were noted to 
have an urticarial rash within the first 3 months of life; two-thirds of the patients had 
urticarial rash within the first few hours of life. All 13 patients had arthropathy or patellar/
epiphyseal overgrowth, and 11 of the 13 patients had both findings. All of the patients had 
neurologic involvement, including one or more of the following: mental retardation, chronic 
meningitis, seizures, papilledema, uveitis, and hearing loss. Papilledema was noted in 11. 
Lymphadenopathy, hepatosplenomegaly, growth retardation, anemia, neutrophilic 
leukocytosis, and an elevated erythrocyte sedimentation rate were observed in all 13 
patients.
Figure 2 illustrates several of the clinical features of NOMID/CINCA syndrome, including 
the facial characteristics, papilledema, the urticarial rash with neutrophilic perivascular 
infiltrates, and severe contractures caused by overgrowth of the femoral epiphysis and 
patella. There was no evidence of synovitis on the contrast-enhanced magnetic resonance 
image shown for patient 922.
Findings of mutation analysis
All 13 patients were screened for CIAS1 mutations by automated bidirectional sequencing of 
PCR-amplified genomic DNA for each of the 9 exons and the exon–intron junctions. In 6 
patients, we identified single-nucleotide substitutions, all of which were in exon 3, that 
resulted in missense amino acid substitutions. Table 1 summarizes the CIAS1 mutations that 
were found in the 13 NOMID/CINCA syndrome patients and lists the number of control 
chromosomes from healthy unrelated individuals tested for the respective mutations.
In the 4 cases in which parental DNA was available, both parents were found to be negative 
for the substitution. Microsatellite analysis confirmed the parental relationships. Thus, the 
findings strongly indicate that the substitution arose de novo in the child. One of the 
mutations, D303N, has been reported as a de novo change in a French patient with MWS 
(35). The same mutation was also present in a father–daughter pair in a rare case of familial 
NOMID/CINCA syndrome (33). In 2 unrelated patients, one Canadian (patient 975) and the 
other Argentinian (patient 996), 2 distinct substitutions at nucleotide 1569 (C→A and C→G, 
respectively) resulted in the substitution of leucine for phenylalanine at residue 523 (F523L).
In 7 patients, bidirectional genomic sequencing failed to identify any changes. There were 
no discernible differences in the clinical features of patients for whom we found mutations 
and those for whom we did not find mutations (Figure 1).
Findings of cytokine studies in a NOMID/CINCA syndrome patient with a CIAS1 mutation
Patient 922, who was found to harbor the D303N CIAS1 mutation, has received followup 
care at the Warren Grant Magnuson Clinical Center of the National Institutes of Health. 
Since CIAS1 is highly expressed in monocytes and granulocytes and has recently been 
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implicated in both NF-κB signaling and IL-1 production and processing (31,32), we 
compared cytokine profiles in this patient with those in controls. At the time the patient was 
studied, his erythrocyte sedimentation rate was 92 mm/hour and his C-reactive protein level 
was 7.11 mg/dl.
As shown in Figure 3a, high levels of IL-1β protein were identified by Western blotting of 
lysates from unstimulated monocytes from patient 922, compared with the levels in 7 
healthy unrelated control subjects, but the patient’s IL-1β response to LPS was blunted. 
Levels of IL-1β mRNA from the patient’s unstimulated PBMCs were also increased (data 
not shown), although not as markedly as was the protein in purified monocytes. In addition, 
3 separate serum IL-1Ra levels were obtained over a period of 6 months, and were found to 
be significantly higher in the patient than in the healthy controls. This finding is consistent 
with observations that endogenously produced IL-1Ra is a homeostatic response to limit the 
proinflammatory effects of pathologically elevated IL-1 (36,37) (Figure 3b).
Expression of mRNA for 4 other cytokines in PBMCs from this patient was examined by 
real-time PCR. IL-3 and IL-5 were of particular interest because of their role in stimulating 
eosinophilia (38,39), a known manifestation of NOMID/CINCA syndrome. As illustrated in 
Figure 3c, IL-3 and IL-5 mRNA levels were, respectively, 7 and 12 times higher than those 
in the healthy controls. IL-6 levels were also of interest because of the recent report of 
cyclical elevations of this cytokine in a patient with MWS (40). IL-6 message in PBMCs 
was found to be more than 35 times higher than that in the controls (Figure 3c). Consistent 
with this finding, serum IL-6 and TNFβ1 levels were found to be elevated when examined 
by ELISA (data not shown). However, as evidenced by the normal TGFβ1 mRNA levels 
(Figure 3c), cytokine production was not globally up-regulated in the PBMCs from this 
patient.
DISCUSSION
The findings of the present study add to the emerging body of data implicating CIAS1 
mutations in a range of autoinflammatory diseases, including MWS, FCAS, and now, 
NOMID/CINCA syndrome. In 6 patients with classic manifestations of NOMID/CINCA 
syndrome, we identified 6 different CIAS1 missense mutations, 5 of which were novel, that 
were not observed in at least 900 control chromosomes examined. Moreover, in 2 unrelated 
NOMID/CINCA syndrome patients, distinct substitutions at the same CIAS1 nucleotide 
position gave rise to the same amino acid change (F523L), an occurrence that would be 
extremely unlikely if these sequence changes were not disease-associated. These data, 
together with the recent report by Feldmann et al (33), strongly implicate CIAS1 mutations 
as a cause of NOMID/CINCA syndrome. The identification of de novo cases both in the 
present series and in that reported by Feldmann and colleagues, coupled with the reduction 
in reproductive fitness observed in the more severely affected NOMID/CINCA syndrome 
patients, probably accounts for the largely sporadic nature of this illness.
Figure 4 depicts all of the CIAS1 mutations, including those identified in the present study, 
that have been associated with autoinflammatory diseases (9,33,35). All 20 of these 
mutations fall within exon 3 of the CIAS1 genomic sequence, and 14 of the 20 mutations 
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result in missense changes in a single domain of cryopyrin, the CIAS1 protein. The pertinent 
region, a nucleotide-binding site domain of the NACHT subfamily (an acronym for 4 
proteins that define the subfamily: NAIP [neuronal apoptosis inhibitor protein], CIITA 
[class II major histocompatibility complex transcription activator], HET-E [incompatibility 
locus protein from Podospora anserina; a bacterial NTPase protein], and TP1 [telomerase-
associated protein 1]), is found in a number of plant, animal, and bacterial proteins involved 
in apoptosis and inflammation, and is thought to be important in regulating their activity 
(41). Three of these mutations (D303N, Q306L, and D309S) are clustered near the Mg++ 
binding site of motif III of the NACHT domain, and there are 4 other clusters (R260W and 
L264H; T348M, A352V, and H358R; T436N, A439V, and A439T; G569R, Y570C, and 
F573S) that suggest less well-defined but perhaps equally important functional sites. It is 
noteworthy that all of the known CIAS1 mutations are missense changes, which suggests 
that more drastic truncating mutations may cause a different phenotype or may be 
incompatible with life.
Mutations in CIAS1 cause MWS, FCAS, and NOMID/CINCA syndrome, and there is no 
apparent clustering of mutations associated with a particular illness (Figure 4). FCAS, 
MWS, and NOMID/CINCA syndrome appear to represent a spectrum of disease, with 
FCAS the mildest and NOMID/CINCA syndrome the most severe. It is therefore tempting 
to speculate that the phenotype determined by a specific mutation is related to its effect on 
cryopyrin function. However, this appears not to be the whole explanation, since two CIAS1 
mutations have been associated with more than one disorder. R260W has been observed in 
both MWS and FCAS (35), while D303N has been documented in MWS (35) and in 
NOMID/CINCA syndrome (ref. 33 and the present study). These findings strongly suggest 
that additional modifier genes or environmental factors play a role in determining the 
disease phenotype.
No CIAS1 mutation has yet been identified in the N-terminal PYRIN domain of cryopyrin. 
This ~90– amino acid motif is also found in the protein of the same name (pyrin) encoded 
by the FMF gene. Manji et al (31) have recently shown that cryopyrin interacts with a 
second protein, ASC (apoptosis-associated speck-like protein with a caspase recruitment 
domain) through homotypic PYRIN domain interactions, leading to NF-κB activation. 
Feldmann and colleagues (33) have proposed that, through this pathway, CIAS1 mutations 
may have an antiapoptotic effect. In light of their demonstration that CIAS1 is expressed in 
chondrocytes, such a hypothesis could explain the peculiar arthropathy of NOMID/CINCA 
syndrome and is consistent with more general discussions of the etiology of 
autoinflammatory diseases (3). A defect in apoptosis might also explain the possible 
increased risk of malignancy in NOMID/CINCA syndrome (14,42).
CIAS1 is also expressed at high levels in leukocytes, predominantly monocytes, 
granulocytes, and T lymphocytes (9,31,33). In addition to the potential proinflammatory 
effect of alterations in NF-κB signaling in white blood cells, cryopyrin has recently been 
shown to regulate IL-1β production through a pathway involving first PYRIN domain 
interactions between cryopyrin and ASC, and then homotypic caspase recruitment domain 
interactions between ASC and caspase 1 (IL-1–converting enzyme) (32,43). Consistent with 
this pathway, we found markedly elevated IL-1β protein on Western analysis of monocyte 
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lysates from a mutation-positive NOMID/CINCA syndrome patient. Moreover, serum 
IL-1Ra levels were also increased, possibly as a homeostatic response to IL-1 signaling 
(36,37). These data raise the possibility that the IL-1 pathway could be specifically targeted 
by further increasing IL-1Ra levels with the newly available therapeutic preparations of this 
biologic agent (44).
Results of quantitative PCR and serum ELISA suggested a more general state of cytokine 
activation, with dramatic increases in the levels of IL-6 message and protein and TNFβ1 
levels. There were also substantial increases in IL-3 and IL-5 message, which may account 
for the peripheral eosinophilia observed in some NOMID/CINCA syndrome patients. In a 
single previously published case of NOMID/CINCA syndrome without neurologic 
involvement (45), serum IL-1, IL-6, and TNF levels were reported to be normal. This 
underscores the need, especially in the light of the present findings, for a more systematic 
analysis of cytokine activation in NOMID/CINCA syndrome.
The data presented in this report also raise the possibility of genetic heterogeneity in 
NOMID/CINCA syndrome. In 7 of the 13 patients with typical features of this disorder, we 
failed to identify CIAS1 mutations by comprehensive sequencing of the 9-exon CIAS1 
coding region, as well as the exon–intron boundaries. Feldmann and colleagues (33) also 
described a mutation-negative patient with skin and joint inflammation but without evidence 
of chronic meningitis. In our present series, there were no major clinical differences between 
mutation-positive and mutation-negative patients. The possibility remains that some of these 
patients may have mutations in the promoter or introns, or they may have large deletions 
that would not be detected by sequencing of genomic DNA. Alternatively, these patients 
may harbor mutations in a cryopyrin homolog or in a cryopyrin-binding protein.
Coupled with the recent report by Feldmann and colleagues, our findings establish NOMID/
CINCA syndrome at the severe end of the spectrum of CIAS1-associated illnesses and 
further extend the list of autoinflammatory diseases caused by pyrin-related proteins. While 
there remain important unanswered questions with regard to genetic heterogeneity, 
pathogenesis, and treatment, discovery of the genetic basis of NOMID/CINCA syndrome 
should lay the foundation for significant advances in the care of patients who have this 
disease.
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Characteristics of the 13 study patients with neonatal-onset multisystem inflammatory 
disease/chronic infantile neurologic, cutaneous, and articular syndrome. CIAS1 mutations 
were found in 6 of the 13 patients. ESR = erythrocyte sedimentation rate.
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Clinical features of neonatal-onset multisystem inflammatory disease/chronic infantile 
neurologic, cutaneous, and articular syndrome in patient 922. Top left, Facial features. Top 
middle, Urticarial rash, which persisted throughout a week-long hospital visit. Top right, 
Contractures of the knees. Bottom left, Funduscopic image, demonstrating papilledema in 
the left eye (present bilaterally). Bottom middle, Skin biopsy sample, showing a mild 
perivascular leukocytic infiltrate, with some eosinophils but no epidermal changes. Bottom 
right, Magnetic resonance image of the right knee, demonstrating the absence of significant 
synovial enhancement and the presence of epiphyseal and patellar bony overgrowth.
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a, Western blot analysis of interleukin-1β (IL-1β) expression in monocytes from patient 922 
(JP) and from a healthy control subject. Monocytes were untreated or were stimulated with 
lipopolysaccharide (LPS) for 24 hours. IL-1β protein was constitutively expressed in the 
untreated cells from the patient but was undetectable in cells from the healthy controls (only 
1 of 7 control samples tested is shown). b, Mean levels of IL-1 receptor antagonist (IL-1Ra) 
in samples obtained from patient 922 at 3 different visits were significantly higher compared 
with the mean level in samples from 4 healthy control subjects, as determined by enzyme-
linked immunosorbent assay. c, Real-time polymerase chain reaction for the expression of 
IL-3, IL-5, IL-6, and transforming growth factor β1 (TGFβ1) mRNA in peripheral blood 
mononuclear cells obtained from patient 922. IL-3, IL-5, and IL-6 mRNA levels were 
significantly elevated compared with the levels in normal controls (horizontal line), and are 
expressed as relative cytokine levels. All samples were normalized to the internal GAPDH 
control.
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Protein structure of cryopyrin (9). All of the 20 mutations that cause familial cold 
autoinflammatory syndrome (FCAS), Muckle-Wells Syndrome (MWS), and/or neonatal-
onset multisystem inflammatory disease (NOMID)/chronic infantile neurologic, cutaneous, 
and articular (CINCA) syndrome have been identified in exon 3 of CIAS1, which encodes 
the NACHT domain. Fourteen of the 20 mutations are located within the NACHT domain, 
and 6 mutations are found in the region of cryopyrin, which flanks the NACHT domain. 
Mutations shown in red cause NOMID/CINCA syndrome, those in blue cause MWS, those 
in green cause FCAS, and those in black are observed in more than one disease. The D303N 
mutation was identified in 2 unrelated NOMID/CINCA syndrome patients (ref. 33 and the 
present study) and has been reported in 1 MWS patient (35). The R260W mutation has been 
reported in 2 FCAS and 2 MWS families (35). LRR = leucine-rich repeat.
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